

2



AD-A190 926

DTIC FILE COPY

Institute Report No. 252

**Mutagenic Potential of Nitroguanidine
in the Mouse Lymphoma Forward Mutation Assay**

John W. Harbell, PhD, MAJ MSC
and
Don W. Korte, Jr, PhD, MAJ MSC

Genetic and Cellular Toxicology Branch
Division of Toxicology

DTIC
ELECTE
FEB 08 1988
S D

DISTRIBUTION STATEMENT A
Approved for public release
Distribution Unlimited

December 1987

Toxicology Series: 159

LETTERMAN ARMY INSTITUTE OF RESEARCH
PRESIDIO OF SAN FRANCISCO, CALIFORNIA 94129

88 2 01 121

Mutagenic Potential of Nitrosoguanidine in the Mouse Lymphoma Forward Mutation Assay--
Harbell and Korte

~~Reproduction of this document in whole or in part is prohibited except with the permission of the Commanding General, Letterman Army Institute of Research, Presidio of San Francisco, California 94129. However, the Defense Technical Information Center is authorized to reproduce the document for United States Government purposes.~~

Destroy this report when it is no longer needed. Do not return to the originator.

Citation of trade names in this report does not constitute an official endorsement or approval of the use of such items.

This material has been reviewed by Letterman Army Institute of Research and there is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the author(s) and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense. (AR 360-5)

Edwin S. Beatrice 14 Dec 81

Edwin S. Beatrice
COL, MC
Commanding

(date)

This document has been approved for public release and sale; its distribution is unlimited.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No 0704-0181
Exp Date Jun 30, 1

1a. REPORT SECURITY CLASSIFICATION Unclassified			1b. RESTRICTIVE MARKINGS		
2a. SECURITY CLASSIFICATION AUTHORITY			3. DISTRIBUTION/AVAILABILITY OF REPORT		
2b. DECLASSIFICATION/DOWNGRADING SCHEDULE			Unlimited		
4. PERFORMING ORGANIZATION REPORT NUMBER(S) Institute Report No. 252			5. MONITORING ORGANIZATION REPORT NUMBER(S)		
6a. NAME OF PERFORMING ORGANIZATION Division of Toxicology		6b. OFFICE SYMBOL (if applicable) SGRD-UL-TO	7a. NAME OF MONITORING ORGANIZATION USA Biomedical Research and Development Laboratory		
6c. ADDRESS (City, State, and ZIP Code) Letterman Army Institute of Research San Francisco, Ca 94129-6800			7b. ADDRESS (City, State, and ZIP Code) Frederick, MD 21701-5010		
8a. NAME OF FUNDING/SPONSORING ORGANIZATION USA Medical Research and Development Cmt.		8b. OFFICE SYMBOL (if applicable)	9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER		
8c. ADDRESS (City, State, and ZIP Code) Fort Detrick, MD 21701-5012			10. SOURCE OF FUNDING NUMBERS	PROGRAM ELEMENT NO. 3E16270A835	PROJECT NO. 835
			TASK NO. AB	WORK UNIT ACCESSION DA30391	
11. TITLE (Include Security Classification) Mutagenic Potential of Nitroguanidine (TP036) in the Mouse Lymphoma Forward Mutation Assay					
12. PERSONAL AUTHOR(S) John W. Harbell, MAJ, MS and Don W. Korte, Jr. MAJ, MS					
13a. TYPE OF REPORT Final		13b. TIME COVERED FROM 11Mar85 to 16Oct85		14. DATE OF REPORT (Year, Month, Day)	15. PAGE COUNT
16. SUPPLEMENTARY NOTATION					
17. COSATI CODES			18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)		
FIELD	GROUP	SUB-GROUP	Mutagenicity, Genetic Toxicology, Mouse Lymphoma Assay, Mutagenesis, In vitro, Nitroguanidine; teratology; toxic tolerances		
19. ABSTRACT (Continue on reverse if necessary and identify by block number)					
<p>The mutagenic potential of nitroguanidine (TP036) was assessed in the mouse lymphoma thymidine kinase forward mutation assay both with and without metabolic activation by rat liver S-9. In the initial range-finding assay, cells were exposed to test compound concentrations ranging from 4 mg/ml to 0.01 mg/ml. The confirmatory assay employed doses from 4 mg/ml to 1 mg/ml. Nitroguanidine did not induce a statistically significant increase in the mutant frequency in either of the two assays. These results indicate that nitroguanidine was not mutagenic under the conditions of this study. Keywords:</p> <p>milligram/milliliter</p>					
20. DISTRIBUTION/AVAILABILITY OF ABSTRACT <input checked="" type="checkbox"/> UNCLASSIFIED UNLIMITED <input type="checkbox"/> SAME AS RPT <input type="checkbox"/> DTIC USERS			21. ABSTRACT SECURITY CLASSIFICATION Unclassified		
22a. NAME OF RESPONSIBLE INDIVIDUAL Edwin S. Beatrice			22b. TELEPHONE (include Area Code) 415-561-3600	22c. OFFICE SYMBOL SGRD-UL-Z	

ABSTRACT

The mutagenic potential of nitroguanidine (TP036) was assessed in the mouse lymphoma thymidine kinase forward mutation assay both with and without metabolic activation by rat liver S-9. In the initial range-finding assay, cells were exposed to test compound concentrations ranging from 4 mg/ml to 0.01 mg/ml. The confirmatory assay employed doses from 4 mg/ml to 1 mg/ml. Nitroguanidine did not induce a statistically significant increase in the mutant frequency in either of the two assays. These results indicate that nitroguanidine was not mutagenic under the conditions of this study.

Key Words: Mutagenicity, Genetic Toxicology, Mouse Lymphoma Assay, Nitroguanidine



The statement on the back of the front cover pertaining to reproduction should be deleted.

Per Major Don W. Korte, Letterman Army Institute of Research/SGRD-UL-TO

Accession For	
NTIS CRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By _____	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	

Title on cover is correct

PREFACE

TYPE REPORT: Mouse Lymphoma GLP Study Report

TESTING FACILITY: US Army Medical Research and Development
Command
Letterman Army Institute of Research
Presidio of San Francisco, CA 94129-6800

SPONSOR: US Army Medical Research and Development Command
US Army Biomedical Research and Development
Laboratory
Frederick, MD 21701-5010
Project Officer: Gunda Reddy, PhD

PROJECT/WORK UNIT/APC: #3E16270A835/180/TLB0

GLP STUDY NUMBER: 85035

STUDY DIRECTOR: MAJ Don W. Korte, Jr., PhD, MS

PRINCIPAL INVESTIGATOR: MAJ John W. Harbell, PhD, MS

REPORT AND DATA MANAGEMENT: A copy of the final report,
retired SOPs, study protocol,
retired stability and purity
data on the test compound, and
an aliquot of the test compound
will be retained in the LAIR
Archives.

TEST SUBSTANCE: Nitroguanidine CAS # 556-88-7

OBJECTIVE: The objective of this study was to determine the
mutagenic potential of Nitroguanidine (TP036) by using the
Mouse Lymphoma Forward Mutation Assay

ACKNOWLEDGMENTS

SGT Steven K. Sano and John Dacey provided research assistance during this study.

SIGNATURES OF PRINCIPAL SCIENTISTS AND MANAGERS INVOLVED IN
THE STUDY

We, the undersigned, declare that GLP study number 85035
was performed under our supervision, according to the
procedures described herein, and that this report is an
accurate record of the results obtained.

Don W. Korte, Jr. 2 DEC 87
DON W. KORTE, JR, PhD / Date
MAJ, MS
Study Director

John W. Harbell 6 Aug 87
JOHN W. HARBELL, PhD / Date
MAJ, MS
Principal Investigator

Conrad R. Wheeler 4 Nov 87
CONRAD R. WHEELER, PhD / Date
DAC
Analytical Chemist



DEPARTMENT OF THE ARMY

LETTERMAN ARMY INSTITUTE OF RESEARCH
PRESIDIO OF SAN FRANCISCO, CALIFORNIA 94129-6800

REPLY TO
ATTENTION OFF

SGRD-ULZ-QA
MEMORANDUM FOR RECORD

19 Nov 87

SUBJECT: Report of GLP Compliance for Study 85035

1. I hereby certify that the protocol for GLP Study 85035 was reviewed on 11 March 1985 and the study inspected 2 April 1985. The phase inspected was exposure of cells to compound.
2. The report entitled "Mutagenic Potential of Nitroguanidine (TPO36) in the Mouse Lymphoma Forward Mutation Assay," Toxicology Series 159, and the raw data were audited on 7 July 1987 and 5 November 1987.

Carolyn M Lewis
CAROLYN M. LEWIS
C, Quality Assurance

TABLE OF CONTENTS

Abstract.....	i
Preface.....	iii
Acknowledgments.....	iv
Signatures of Principal Scientists.....	v
Report of the Quality Assurance Unit.....	vi
Table of Contents.....	vii
BODY OF THE REPORT	
INTRODUCTION.....	1
Objective of the Study	1
MATERIALS AND METHODS	
Test Compound	1
Chemical Preparation	2
Positive Controls	2
Cells	2
Medium	2
Metabolic Activation System	3
Assay Format	3
Cloning	4
Assay Acceptance Criteria	5
DATA EVALUATION	
Cell Replication and Survival	6
Mutant Frequency	6
Criteria for a Positive or Negative Response	6
Deviations from the Protocol/SOP	7
RESULTS.	7
DISCUSSION.....	12
CONCLUSION.....	13
REFERENCES.....	14
GLOSSARY.....	15
APPENDICES.....	17
OFFICIAL DISTRIBUTION LIST.....	25

Mutagenic Potential of Nitroguanidine (TP036) in the Mouse
Lymphoma Forward Mutation Assay -- Harbell and Korte

Nitroguanidine, a primary component of US Army triple-base propellants, is now produced in a Government-owned contractor-operated ammunition plant. The US Army Biomedical Research and Development Laboratory (USABRDL), as part of its mission to evaluate the environmental and health hazards of military-unique propellants generated by US Army munitions manufacturing facilities, conducted a review of the nitroguanidine database and identified significant gaps in the toxicity data (1). The Division of Toxicology, LAIR, was tasked by USABRDL to develop a genetic and mammalian toxicity profile for nitroguanidine, related intermediates/by-products of its manufacture, and its environmental degradation products.

Objective of the Study

The objective of this study was to determine the mutagenic potential of nitroguanidine (TP036) by using the Mouse Lymphoma Forward Mutation Assay.

MATERIALS AND METHODS

Nitroguanidine was evaluated for cytotoxicity and mutagenicity according to LAIR SOP, OP-STX-71 (2).


Test Compound

Chemical name: Nitroguanidine

LAIR Code name: TP036

Chemical Abstracts Service Registry No.: 556-88-7

Structural formula:



Empirical formula: $\text{CH}_4\text{N}_4\text{O}_2$

Storage: Nitroguanidine was obtained from Hercules Aerospace Division, Sunflower Army Ammunition Plant, DeSoto, Kansas (lot no. SOW84k101 A001 for the initial and SOW83H001-004 for the confirmatory assay) and was assigned the LAIR

Harbell--2

Code number TP036. The test compound was stored at room temperature in a bunker on the Presidio of San Francisco. Small amounts of test compound were stored at room temperature in the laboratory just before use.

Chemical Properties/Analysis: Data characterizing the chemical composition and purity of the test material were prepared by the Division of Toxicology, LAIR, Presidio of San Francisco, CA (Appendix A).

Chemical Preparation

Nitroguanidine was dissolved directly in Fisher's Medium without serum with a final concentration of 4 mg/ml. This concentration is close to saturation for nitroguanidine in an aqueous medium (1).

Positive Controls

Ethyl methanesulfonate (EMS) (Sigma lot no. 83F-0279), added directly to the culture medium so as to provide a final concentration of 0.32 mg/ml, was used as the positive control for the assays conducted without metabolic activation. A stock solution of 2-acetamide fluorene (2AAF) (Sigma lot no. 113F-3679) in DMSO (Sigma lot no. 113F-0450) of 50 mg/ml (first assay) or 5 mg/ml (confirmatory assay) was prepared. One hundred microliters of this stock were used (0.5 or 0.05 mg/ml final concentration, respectively, in the two assays) as the positive control for assays conducted with metabolic activation. The final DMSO concentration of the 2AAF-treated cultures did not exceed 1%. Both positive controls were prepared fresh on the day of assay.

Cells

Mouse lymphoma cells L5178Y 3.7.2C TK[±] were provided by Dr. Donald Clive, PhD, Burroughs Wellcome Co, Research Triangle Park, NC 27709. These cells were maintained in antibiotic-free Fisher's Medium for Leukemic Cells of Mice (Fisher's Medium) supplemented with 10% horse serum. Six days before each assay began, the cell population was cleared of spontaneous thymidine kinase negative mutants by methotrexate treatment (2) and screened for mycoplasma and other contaminants by using the 3T6 co-culture technique (3). No nonnuclear DNA was detected after four days of co-culture, and thus the cell line was presumed to be uncontaminated.

Medium

Powdered Fisher's Medium (basic) was purchased from Sigma Chemical Co (lot no. 113F-4710-1) and prepared in 10 mM HEPES buffered glass distilled water (pH 7.3). The medium

was immediately filter sterilized. The sterile medium was supplemented with l-glutamine (2 mM) and sodium pyruvate (1 mM). Sterile horse serum (lot no. 310437) was obtained from Sterile Systems Inc, Logan, Utah, and was heat inactivated (56°C for 30 minutes) before use. Fisher's Medium was supplemented with horse serum at 5%, 10%, or 20% (volume/volume) final concentration. These were designated F5p, F10p, and F20p, respectively, after the standard notation of Clive (4).

Metabolic Activation System

The metabolic activation system was composed of Aroclor-induced rat liver 9000 g supernatant fraction (S-9) and an NADPH-regenerating system provided by the cofactor mixture. Cofactor mixture, consisting of 2 mg/ml of NADP (Sigma lot no. 123F-7095 and 100F-7225) and 14.25 mg/ml of sodium isocitrate (Sigma lot no. 64F-3825), was prepared in Fisher's Medium without serum. In order to achieve the desired final nitroguanidine concentrations, cofactor mixture containing nitroguanidine was also prepared. This solution was prepared separately and mixed with normal cofactor mixture to obtain the desired concentration. These solutions were prepared immediately before use. When metabolic activation was used, 3 ml of cofactor solution were combined with 6 ml of cell suspension containing the treatment compound. Then 1 ml of S-9 was added to each group. Litton Aroclor-induced rat liver S-9 lot no. (RDK120) was used for each assay. Vials were thawed immediately before use.

Assay Format

Dosing: Stock cultures of L5178Y 3.7.2C cells were prepared for use by clearing spontaneous mutants and checking for contamination (see "Cells" above). Only cleared and noncontaminated cell populations were used for these assays. L5178Y cells were counted with a Coulter Counter model ZM (Coulter Electronic Inc, Hialeah, Florida) and resuspended in Fisher's Medium with 5% horse serum (F5p) at a concentration of 10^6 cells/ml. After one hour, 6 ml of the cell suspension were pipetted into each culture tube. The cells were then centrifuged down and the supernatant medium drawn off. The cells were then resuspended in F0p containing the desired concentration of nitroguanidine. For groups treated without metabolic activation, 9.7 ml were added, while those with metabolic activation received 5.7 ml. Three hundred microliters of horse serum were added to bring the serum concentration to 3%. Positive controls were added (see Tables 1 and 3 for concentrations). Negative controls were prepared for both the metabolic activation series and the nonactivation series. The groups of the metabolic activation series received 3 ml of cofactor mixture and 1 ml of freshly thawed S-9 suspension. The cofactor mixture also contained

Harbell--4

nitroguanidine in some cases to achieve the desired final compound concentration. The low serum (3%) concentration was intended to reduce the possible interaction (and inactivation) of test compounds with the serum proteins (4).

These cultures were maintained at 37°C on a roller drum for 4 hours, washed twice with Fisher's Medium containing 10% horse serum (F10p), resuspended in 20 ml of F10p, and returned to the roller drum. Ten percent serum in the medium provided for rapid growth in suspension culture.

Culturing: Approximately 24 hours after the cultures were first exposed, a sample of each culture was trypsin-treated for 10 minutes to produce a single cell suspension for counting. This suspension was then diluted to the appropriate concentration range and counted (average of three counts). The remaining cells from each culture were then diluted to 3×10^5 cells/ml in 20 ml of F10p and returned to the roller drum. After approximately 48 hours, an aliquot from each culture was again counted. All cultures to be cloned at this point were diluted to 3×10^5 cells/ml in Fisher's Medium with 20% horse serum (F20p). Twenty percent serum was used during cloning to enhance the absolute cloning efficiency.

Cloning

Nonselective: Soft agar cloning was used to determine the percentage of viable cells (viable count) and thymidine kinase negative mutants (mutant count) in each control and treated culture. To determine the percentage of viable cells, a portion of each freshly diluted culture (3×10^5 cells/ml) was further diluted to 600 cells/ml in F20p. One milliliter of this suspension was diluted in 105 ml of F20p containing 0.4% agar (Sigma lot no. 123F-0293) at 37°C. After vigorous mixing, this suspension of 5.7 cells/ml was dispensed into three 100 mm petri dishes (33 ml/dish). The extra 5 ml were provided to compensate for medium that foamed or adhered to the sides and thus could not readily be dispensed into the petri plates. The agar was allowed to harden at room temperature in the laminar flow hood (about 10 minutes).

Selective: To determine the percentage of thymidine kinase negative mutants, a similar but selective cloning procedure was performed. Ten milliliters of the 3×10^5 cells/ml suspension were diluted with 95 ml of F20p with 0.4% agar (final concentration) which contained 1 µg/ml of trifluorothymidine (TFT) (Sigma lot no. 94F-0351). TFT was used to arrest the growth of all cells that contained thymidine kinase. After mixing, 33 ml of this 2.86×10^4

cells/ml suspension were placed into each of three 100-mm petri dishes.

After hardening, both the mutant and viable count dishes were incubated for 11 days at 37°C in a humidified atmosphere of 95% air and 5% CO₂. The number of colonies on each plate was then determined by using a Biotran II Automated Colony Counter (New Brunswick Scientific Co, Edison, New Jersey) with the size setting on zero.

Assay Acceptance Criteria

The following criteria are required, according to Brusick (5), for a valid assay.

Cloning Efficiency: The minimum negative control viable count cloning efficiency (mean count/mean number of cells plated) should be 70% or greater for the negative control cultures not treated with the activation mixture. A 100% cloning efficiency may be exceeded due to the delay between cell counts and dilutions during which the cells continue to divide. However, since the dilutions for the selective and nonselective cloning suspensions are made at the same time, the ratio between the two should not change even with the delay.

Cell Replication: The cells in the negative control cultures (without S-9 activation) should undergo at least a 15-fold increase in cell number over the two days of suspension culture. Negative control cultures treated with the metabolic activation mixture characteristically show slightly less growth and therefore may not undergo the 15-fold increase.

Positive Control Responses: A statistically significant mutagenic response (see below) must be induced by the positive controls. Failure to induce a mutagenic response by the positive activation control (2AAF) would invalidate only the activation series provided that the EMS (nonactivation control) induced an appropriate response.

Treatment Concentration: In the absence of strong mutagenic activity (e.g. possible nonmutagen), cells should be exposed to the test compound concentration to the limits of solubility (usually up to 5 mg/ml) or to the point where suspension growth is reduced by cytotoxicity to 10% of controls. In these assays, the solubility of nitroguanidine limited the upper dose concentration.

Harbell--6

DATA EVALUATION

Cell Replication and Survival

The combined activity of cell replication and survival for each control and treatment group is the product of suspension growth during the two days after exposure and the viable count cloning efficiency (2). Absolute suspension growth (ASG) is measured as a fold increase (usually 15- to 20-fold) in the control cultures over the 48-hour period. For example, the EMS treated culture in the initial assay (Table 1) grew from 3×10^5 cells/ml to 1.059×10^6 cells/ml, a 3.53-fold increase, during the first 24 hours. The culture was then diluted to 3×10^5 cells/ml and allowed to continue growing for another 24 hours. At that point, the cell concentration was 1.320×10^6 cells/ml, a 4.4-fold increase. Thus the total growth was $3.53 \times 4.4 = 15.4$ -fold increase over two days. Relative suspension growth (RSG) compares the treated groups against the appropriate negative controls. Absolute cloning efficiency (ACE) is the observed number of viable count clones compared to the expected number of 189 per plate (5.7 cells/ml \times 33 ml = 189 cells). Relative cloning efficiency (RCE) compares the treated groups with their respective negative controls. Thus, absolute cell survival (ACS) is the product of the suspension growth and absolute cloning efficiency while the relative cell survival (RCS) is the treated ACS compared to the control ACS.

Mutant Frequency

The mutant frequency (MF) is the mean selective plate count divided by the mean nonselective plate count multiplied by the dilution factor (2×10^{-4}). The dilution factor is derived from the ratio of the number of cells plated per ml in the nonselective plates divided by the number of cells plated per ml in the selective plates ($5.7 / [2.86 \times 10^4] = 2 \times 10^{-4}$). The induced mutant frequency (IMF) in the treated groups is the observed mutant frequency less the spontaneous mutant frequency of the negative controls. Again, nonactivation and activation series are compared separately. The variance and standard error (SE) of the mutant frequency are calculated by using the mean selective and nonselective plate counts and with an assumed dilution variance of 10% (2, 4).

Criteria for a Positive or Negative Response

An individual treatment concentration is considered positive if the assay is valid, the cell survival is at least 10% of controls, and the induced mutant frequency is at least three times ($p < 0.01$) the standard error of that mutant frequency. A test compound is considered mutagenic if it

yields a correlated positive dose response through several (usually three) treatment concentrations (4-6).

A compound is considered nonmutagenic in this system if a valid assay does not yield a positive response and the limits of compound solubility (up to 5 mg/ml) or 90% reduction in cell survival has been reached. Normally, a determination of mutagenic potential is not made on the basis of only one assay. Both positive and negative assays are confirmed.

Deviations from the Protocol/SOP

In the initial assay, the concentration of 2AAF was 0.5 mg/ml instead of 0.05 mg/ml, which accounts for the extreme toxicity observed. This toxicity and the mutant frequency does, however, demonstrate that the activation system was functioning.

RESULTS

Nitroguanidine was assayed two times, one initial assay and one confirmatory assay. The compound exposure concentration and resulting data are presented in Tables 1 through 4, while the raw data are contained in Appendix B.

The initial assay (Tables 1 and 2) covered a dose range of 4 to 0.01 mg/ml. Absolute suspension growth and absolute cloning efficiency for the negative controls were within prescribed limits. The apparent greater-than-100% absolute cloning efficiency was the result of the time delay between cell counting and dilution of these samples. Both positive controls produced a statistically significant mutagenic response as required for a valid assay. The test compound, nitroguanidine, did not produce significant mutagenic activity at any concentration tested.

The confirmatory assay (Tables 3 and 4) covered a dose range of 4 to 1 mg/ml. This assay was also valid in terms of cell growth, cloning efficiency, and positive control-induced mutagenic activity. Again no statistically significant mutagenic activity was induced by nitroguanidine.

Table 1

Cell Survival Data from the Initial Assay

Treatment	S-9	Cell Count		ASG ^a	RSG ^b	VC ^c	ACE ^d	RCE ^e	RCS ^f
		Day 1	Day 2						
		(x 10 ³ /ml)							
Control ^g	-	1032	1347	15.30	100	250	132	100	100
EMS 0.32 mg/ml	-	1059	1320	15.40	101	217	115	87	88
TP036 4.0 mg/ml	-	891	1254	12.60	82	276	146	110	90
TP036 2.0 mg/ml	-	848	1484	13.72	90	228	120	91	81
TP036 1.0 mg/ml	-	949	1337	14.40	94	245	129	98	92
TP036 0.5 mg/ml	-	994	1333	14.52	95	246	130	98	92
TP036 0.1 mg/ml	-	1029	1359	15.30	100	259	137	104	104
TP036 0.05 mg/ml	-	1155	1271	16.38	107	270	143	108	116
TP036 0.01 mg/ml	-	1112	1257	15.54	102	246	130	98	100
Control	+	880	1394	13.34	100	235	124	100	100
2AAF 0.5 mg/ml	+	77	136	0.45	3	28	15	12	0
TP036 3.66 mg/ml	+	756	1360	11.25	84	257	136	109	92
TP036 2.0 mg/ml	+	819	1299	11.61	87	268	142	114	100
TP036 1.0 mg/ml	+	867	1221	11.89	88	275	146	117	104
TP036 0.5 mg/ml	+	808	1394	12.42	93	250	132	106	99
TP036 0.1 mg/ml	+	906	1326	13.20	98	249	132	106	104
TP036 0.05 mg/ml	+	1002	1147	12.54	94	232	123	99	93
TP036 0.01 mg/ml	+	929	1127	11.78	86	307	162	131	113

a Absolute suspension growth = Total fold increase in suspension culture

b Relative suspension growth = treated/control x 100

c Viable Clone Count = mean of 3 plates

d Absolute Cloning Efficiency = viable clone count/189 x 100

e Relative Cloning Efficiency = treated/control x 100

f Relative Cell Survival = absolute cell survival

treated/absolute cell survival control x 100

g Mean values from both negative controls

Table 2

Mutagenesis Data from the Initial Assay

Treatment	S-9	RCS ^a	MF ^b (x10 ⁻⁶)	IMF ^c (x10 ⁻⁶)	SE ^d (x10 ⁻⁶)	IMF/SE ^e
Control ^f	-	100	23.9			
EMS 0.32 mg/ml	-	88	50.1	26.2	6.66	3.93
TP036 4.0 mg/ml	-	90	15.9	-7.9		
TP036 2.0 mg/ml	-	81	14.3	-9.5		
TP036 1.0 mg/ml	-	92	17.7	-6.2		
TP036 0.5 mg/ml	-	92	14.1	-9.8		
TP036 0.1 mg/ml	-	104	11.6	-12.3		
TP036 0.05 mg/ml	-	116	20.5	-3.4		
TP036 0.01 mg/ml	-	100	24.7	0.8	3.69	0.21
Control	+	100	46.0	0.0		
2AAF 0.5 mg/ml	+	0	178.6	132.6	33.52	3.96
TP036 3.66 mg/ml	+	92	34.0	-12.0		
TP036 2.0 mg/ml	+	100	30.8	-15.2		
TP036 1.0 mg/ml	+	104	30.0	-15.9		
TP036 0.5 mg/ml	+	99	38.5	-7.6		
TP036 0.1 mg/ml	+	104	24.9	-21.1		
TP036 0.05 mg/ml	+	93	33.3	-12.7		
TP036 0.01 mg/ml	+	113	41.1	-5.0		

a Relative Cell Survival = absolute cell survival treatment/absolute cell survival controls x 100

b Mutant Frequency = mutant clone count/viable clone count x dilution factor

c Induced Mutant Frequency = treated mutant frequency - control mutant frequency

d Standard Error is calculated only when the IMF > 0.

e Ratio of the IMF to SE > 3 indicates a positive treatment response

f Mean values from both negative controls

Table 3

Cell Survival Data from the Confirmatory Assay

Treatment	S-9	Cell Count		ASG ^a	RSG ^b	VCC ^c	ACE ^d	RCE ^e	RCS ^f
		Day 1	Day 2						
		(x 10 ³ /ml)							
Control ^g	-	1178	1662	21.65	100	169	89	100	100
EMS 0.32 mg/ml	-	705	1610	12.96	60	160	84	95	57
TP036 4.0 mg/ml	-	841	1576	14.84	69	177	94	105	72
TP036 2.0 mg/ml	-	1028	1657	18.70	86	163	86	97	83
TP036 1.0 mg/ml	-	1074	1649	19.80	91	172	91	102	93
Control ^g	+	793	1590	14.05	100	173	92	100	100
2AAF 0.05 mg/ml	+	589	1492	10.00	71	169	89	98	70
TP036 3.84 mg/ml	+	630	1552	10.92	78	157	83	91	71
TP036 2.0 mg/ml	+	689	1602	12.19	87	130	69	75	65
TP036 1.0 mg/ml	+	654	1632	11.88	85	157	83	91	77

^a Absolute suspension growth = Total fold increase in suspension culture

^b Relative suspension growth = treated/control x 100

^c Viable Clone Count = mean of 3 plates

^d Absolute Cloning Efficiency = viable clone count/189 x 100

^e Relative Cloning Efficiency = treated/control x 100

^f Relative Cell Survival = absolute cell survival treated/absolute cell survival control x 100

^g Mean values from both negative controls

Table 4

Mutagenesis Data from the Confirmatory Assay

Treatment			S-9	RCS ^a	MF ^b ($\times 10^{-6}$)	IMF ^c (10×10^{-6})	SE ^d ($\times 10^{-6}$)	IMF/SE ^e
Control ^f			-	100	60.8			
EMS	0.32	mg/ml	-	57	395.4	334.6	45.33	7.38
TP036	4.0	mg/ml	-	72	42.1	-18.7		
TP036	2.0	mg/ml	-	83	44.3	-16.5		
TP036	1.0	mg/ml	-	93	67.3	6.5	8.95	0.73
Control ^f			+	100	59.4			
2AAF	0.05	mg/ml	+	70	118.2	58.8	14.63	4.02
TP036	3.84	mg/ml	+	71	58.7	-0.7		
TP036	2.0	mg/ml	+	65	63.1	3.7	9.07	0.41
TP036	1.0	mg/ml	+	77	65.8	6.4	8.97	0.71

^a Relative Cell Survival = absolute cell survival treatment/absolute cell survival controls $\times 100$

^b Mutant Frequency = mutant clone count/viable clone count \times dilution factor

^c Induced Mutant Frequency = treated mutant frequency - control mutant frequency

^d Standard Error of the mutant frequency calculated only when the IMF > 0 .

^e Ratio of the IMF to SE > 3 indicates a positive treatment response

^f Mean values from both negative controls

DISCUSSION

The mutagenicity of nitroguanidine was evaluated in a mouse lymphoma forward mutation study consisting of an initial and a confirmatory assay. The results of this study indicated that nitroguanidine was not mutagenic in the mouse lymphoma test system. Both assays met the acceptance criteria for cloning efficiency, cell replication, positive control responses, and maximum test compound concentrations. The cloning efficiency of the negative controls without metabolic activation was greater than 70%. The total cell replication in suspension culture of these same controls was greater than 15 fold for the two days of culture. Both EMS and 2AAF induced statistically significant mutagenic responses. Spontaneous mutation rates were well within published values of $25-115 \times 10^{-6}$ without activation and $25-135 \times 10^{-6}$ with activation (3). The highest concentration of nitroguanidine tested was 4 mg/ml, which is nearly the limit of solubility for this compound.

Metabolic activation with rat liver S-9 did not significantly alter either the cytotoxicity or mutagenicity of nitroguanidine. Even at the highest doses, cytotoxicity was mild, with relative cell survivals of 70% or greater in all cases.

Nitroguanidine has been reported to cause significant chromosome damage in Chinese hamster fibroblasts (7). For this study, Ishidata and Odashima used a dose of 4 mg/ml for 24 hours and found 26% of the metaphases to have chromosomal aberrations, principally gaps, breaks and translocations. Our data from the CHO Sister Chromatid Exchange Assay (SCE) showed nitroguanidine to be very toxic at that dose over a 24-hour exposure (8). Most of the metaphases detected were from first division cells, and even those that showed some differential staining had not gone through two complete replication cycles in the BrdU-containing medium. Examination of the metaphases from this dose group did not reveal the chromosomal aberrations reported previously. Furthermore, lower concentrations that were less cytotoxic did not induce an increase in SCEs. Thus our data are at odds with those of Ishidata and Odashima (7) though the test systems were by no means identical (e.g. different cell lines, presence of BrdU, and different chromosome preparation).

Nitroguanidine was also negative in the Ames Salmonella/Mammalian Microsome Assay (8).

CONCLUSION

The mutagenic potential of nitroguanidine was evaluated in the mouse lymphoma thymidine kinase forward mutation assay. Nitroguanidine was not mutagenic under conditions of this study.

REFERENCES

1. Kenyon KF. A data base assessment of environmental fate aspects of nitroguanidine. Technical Report 8214. Frederick, Maryland: US Army Medical Bioengineering Research and Development Laboratory, December 1982.
2. L5178Y TK⁺/⁻ Mouse lymphoma mutation assay. LAIR Standard Operating Procedure OP-STX-71. Presidio of San Francisco, California: Letterman Army Institute of Research, 7 March 1985.
3. Detection of mycoplasma in cell cultures. LAIR Standard Operating Procedure OP-STX-92. Presidio of San Francisco, California: Letterman Army Institute of Research, 1 March 1985.
4. Turner N, Batson AG, Clive D. Procedures for the L5178Y TK ⁺/⁻ TK⁻/⁻ mouse lymphoma cell assay. In: Kilbey BJ, Legator M, Nichols W, Ramel C, eds. Handbook of mutagenicity test procedures. New York: Elsevier Science Pub, 1984:239-268.
5. Brusick D. Genetic toxicology. In: Hayes AW, eds. Principles and methods of toxicology. New York: Raven Press, 1982:223-272.
6. Clive D, Johnson KO, Spector JFS, Batson AG, Brown MMM. Validation and characterization of the L5178Y TK⁺/⁻ mouse lymphoma mutagen assay system. Mutat Res 1979; 59:61-108.
7. Ishidata M, Odashima S. Chromosome tests with 134 compounds on Chinese hamster cells in vitro--a screening for chemical carcinogens. Mutat Res 1977; 48:337-354.
8. Harbell JW, Witcher LD, Sebastian SE, Korte DW. Studies on the mutagenic potential of nitroguanidine and nitrosoguanidine. Proceedings of the 1987 JANNAF Safety and Environmental Protection Subcommittee Meeting, 5-7 May 1987. Cleveland, Ohio. in press.

Glossary

- Absolute Cell Survival:** The product of the population's total fold increase in growth in suspension culture multiplied by the absolute cloning efficiency under nonselective conditions.
- Absolute Cloning Efficiency:** The number of colonies counted on the nonselective plates divided by the number of cells originally plated x 100.
- Fold Increase in Suspension Growth:** The quotient of the cell concentration at the end of the growth period divided by the starting cell concentration.
- Induced Mutant Frequency:** The mutant frequency of the treated population less the mutant frequency of the control population.
- Mutant Frequency:** The ratio of the number of colonies on the selective plates divided by the number of colonies on the nonselective plates multiplied by the dilution factor. The dilution factor is the ratio of the number of cells plated on the nonselective plates divided by the number plated on the selective plates.
- Relative Cell Survival:** The absolute cell survival of the treated population divided by the absolute cell survival of the negative control population x 100.
- Relative Cloning Efficiency:** The absolute cloning efficiency of the treated population divided by the absolute cloning efficiency of the control population x 100.
- Relative Suspension Growth:** Total fold increase in cell number during suspension growth of the treated population divided by the total fold increase in cell number during suspension growth of the negative control population x 100.
- Total Fold Increase in Suspension Growth:** The product of the fold increase for the first day times the fold increase for the second day.

APPENDICES

Appendix A. Chemical Data	19
Appendix B. Raw Data	21

CHEMICAL DATA


Chemical name: Nitroguanidine (NGu)

Other listed names: Guanidine, Nitro; alpha-Nitroguanidine;
beta-Nitroguanidine

Chemical name: Nitroguanidine (NGu)

LAIR Code: TP036A

Structural formula:



Molecular formula: $\text{CH}_4\text{N}_4\text{O}_2$

Molecular weight: 104.1

pH range of dosing suspensions: 6.7 - 7.4(1)

Physical state: White Powder

Melting point: 232°(2)

Source: Hercules Aerospace Division
Sunflower Ammunition Plant
DeSoto, Kansas

Lot No. SOW64K010-A-001

1. Wheeler CR. Nitrocellulose-Nitroguanidine Projects
Laboratory Notebook #85-12-022, p 26. Letterman Army
Institute of Research, Presidio of San Francisco, CA.
2. Fedoroff BT, Sheffield OE. Encyclopedia of explosives
and related items. Vol V. Dover, New Jersey: Picatinny
Arsenal 1975: G154.

Nitroguanidine Chemical Data (continued)

Analytical data/purity: The major peaks in the infrared spectrum of the compound were observed at 3450, 3396, 3342, 3278, 3201, 1666, 1634, 1525, 1404, 1314, 1151, 1045, 782 cm^{-1} (3). The spectrum obtained for the test compound in our laboratory was identical to the Sadtler standard spectrum for nitroguanidine (4). HPLC showed only one peak (retention time 4.9 min) (5). The conditions employed were as follows: column, Brownlee RP-18 (4.6 x 250 mm); solvent 10% methanol/90% water, flow rate 0.7 ml/min; oven temperature, 50°C; monitoring wavelength, 265 nm.

3. Wheeler CR. Nitrocellulose-Nitroguanidine Projects. Laboratory Notebook #85-12-022, p. 22-23. Letterman Army Institute of Research, Presidio of San Francisco, CA.
4. Sadtler Research Laboratory, Inc. Sadtler Standard spectra. Philadelphia: The Sadtler Research Laboratory, Inc., 1962: Infra-red spectrogram #21421.
5. Wheeler CR. Nitrocellulose-Nitroguanidine Projects Laboratory Notebook #85-12-022, pp. 24-25. Letterman Army Institute of Research, Presidio of San Francisco, CA.

**Raw Data from the Initial Assay without Activation
2 April 1985**

Treatment	S-9	Cell Counts Day 1 (x 10 ³ /ml)	Cell Counts Day 2 (x 10 ³ /ml)	Viable Clone Counts	Selective Clone Counts
Control	-	961	1207	261	24
		955	1196	253	23
		1010	1152	252	20
EMS 0.32 mg/ml	-	1078	1356	223	55
		1081	1308	211	41
		1017	1297	217	67
TP036 4.0 mg/ml	-	925	1321	291	23
		859	1232	263	20
		889	1209	274	23
TP036 2.0 mg/ml	-	845	1509	236	14
		852	1472	200	16
		847	1472	247	19
TP036 1.0 mg/ml	-	942	1341	252	13
		945	1305	252	27
		961	1364	230	25
TP036 0.5 mg/ml	-	953	1364	240	22
		1015	1345	260	15
		1013	1290	238	15
TP036 0.1 mg/ml	-	1015	1373	250	16
		1040	1394	278	11
		1032	1310	248	18
TP036 0.05 mg/ml	-	1149	1286	300	22
		1158	1277	248	30
		1159	1250	263	31
TP036 0.01 mg/ml	-	1130	1277	243	26
		1086	1232	234	31
		1120	1263	261	34
Neg	-	1077	1526	242	37
		1119	1493	252	36
		1022	1509	239	38

**Raw Data from the Initial Assay with Activation
2 April 1985**

Treatment	S-9	Cell Counts Day 1 (x 10 ³ /ml)	Cell Counts Day 2 (x 10 ³ /ml)	Viable Clone Counts	Selective Clone Counts
Control	+	898	1418	227	53
		886	1403	245	60
		857	1361	233	49
2AAF 0.5 mg/ml	+	65	158	37	23
		91	125	24	21
		74	125	23	31
TP036 3.66 mg/ml	+	755	1360	260	43
		700	1355	260	44
		813	1365	250	44
TP036 2.0 mg/ml	+	856	1357	285	40
		799	1297	254	44
		803	1244	266	40
TP036 1.0 mg/ml	+	869	1200	279	32
		875	1212	263	44
		858	1251	284	48
TP036 0.5 mg/ml	+	781	1348	236	51
		827	1418	258	47
		815	1417	255	46
TP036 0.1 mg/ml	+	901	1322	238	23
		916	1362	266	35
		901	1295	243	35
TP036 0.05 mg/ml	+	997	1168	197	38
		1000	1152	252	39
		1010	1120	247	39
TP036 0.01 mg/ml	+	951	1140	320	73
		940	1110	307	58
		896	1132	293	58

**Raw Data from the Confirmatory Assay without
Activation
3 October 1985**

Treatment	S-9	Cell Counts Day 1 (x 10 ³ /ml)	Cell Counts Day 2 (x 10 ³ /ml)	Viable Clone Counts	Selective Clone Counts
Control	-	1135	1744	177	35
		1166	1745	159	44
		1146	1709	163	41
EMS 0.32 mg/ml	-	706	1597	144	294
		715	1594	149	320
		693	1640	186	333
TP036 4.0 mg/ml	-	837	1576	167	41
		865	1565	171	39
		820	1586	194	32
TP036 2.0 mg/ml	-	977	1674	157	25
		1075	1667	156	36
		1031	1629	179	48
TP036 1.0 mg/ml	-	1109	1695	162	60
		1024	1662	167	56
		1088	1590	188	58
Control	-	1226	1557	174	64
		1192	1591	172	58
		1202	1621	168	66

**Raw Data from the Confirmatory Assay with Activation
3 October 1985**

Treatment	S-9	Cell Counts Day 1 (x 10 ³ /ml)	Cell Counts Day 2 (x 10 ³ /ml)	Viable Clone Counts	Selective Clone Counts
Control	+	777	1566	186	57
		736	1546	159	52
		736	1455	166	48
EMS 0.05 mg/ml	+	605	1483	162	90
		576	1524	169	104
		585	1470	175	105
TP036 3.84 mg/ml	+	641	1524	159	54
		612	1582	165	38
		637	1549	146	46
TP036 2.0 mg/ml	+	719	1560	133	40
		650	1637	137	38
		698	1609	120	45
TP036 1.0 mg/ml	+	657	1675	164	58
		642	1612	160	45
		664	1610	147	52
Control	+	853	1714	162	43
		831	1668	175	56
		823	1593	189	57

OFFICIAL DISTRIBUTION LIST

Commander
US Army Medical Research
& Development Command
ATTN: SGRD-RMS/Mrs. Madigan
Fort Detrick, MD 21701-5012

Defense Technical Information Center
ATTN: DTIC/DDAB (2 copies)
Cameron Station
Alexandria, VA 22304-6145

Office of Under Secretary of Defense
Research and Engineering
ATTN: R&AT (E&LS), Room 3D129
The Pentagon
Washington, DC 20301-3080

The Surgeon General
ATTN: DASG-TLO
Washington, DC 20310

HQ DA (DASG-ZXA)
WASH DC 20310-2300

Commandant
Academy of Health Sciences
US Army
ATTN: HSHA-CDM
Fort Sam Houston, TX 78234-6100

Uniformed Services University of
Health Sciences
Office of Grants Management
4301 Jones Bridge Road
Bethesda, MD 20814-4799

US Army Research Office
ATTN: Chemical and Biological
Sciences Division
PO Box 12211
Research Triangle Park, NC 27709-2211

Director
ATTN: SGRD-UWZ-L
Walter Reed Army Institute of Research
Washington, DC. 20307-5100

Commander
US Army Medical Research Institute
of Infectious Diseases
ATTN: SGRD-ULZ-A
Fort Detrick, MD 21701-5011

Commander
US Army Medical Bioengineering Research
and Development Laboratory
ATTN: SGRD-UBG-M
Fort Detrick, Bldg 568
Frederick, MD 21701-5010

Commander
US Army Medical Bioengineering
Research & Development Laboratory
ATTN: Library
Fort Detrick, Bldg 568
Frederick, MD 21701-5010

Commander
US Army Research Institute
of Environmental Medicine
ATTN: SGRD-UE-RSA
Kansas Street
Natick, MA 01760-5007

Commander
US Army Research Institute of
Surgical Research
Fort Sam Houston, TX 78234-6200

Commander
US Army Research Institute of
Chemical Defense
ATTN: SGRD-UV-AJ
Aberdeen Proving Ground, MD 21010-5425

Commander
US Army Aeromedical Research
Laboratory
Fort Rucker, AL 36362-5000

AIR FORCE Office of Scientific
Research (NL)
Building 410, Room A217
Bolling Air Force Base, DC 20332-6448

Commander
USAFSAM/TSZ
Brooks Air Force Base, TX 78235-5000

Head, Biological Sciences Division
OFFICE OF NAVAL RESEARCH
800 North Quincy Street
Arlington, VA 22217-5000

Commander
Naval Medical Command-02
Department of the Navy
Washington, DC 20372-5120

Wellspring Communications
Salem House
P.O. Box 733
Marshall, VA 22115